Authors
Ziteng Yu, Xilin Chen, Kaibin Xie, Xiangyi Xu, Jianbin Pan, Tianyu Li, Wenjuan Ma, Duanping Sun
Published in
Advanced healthcare materials. Pages e71807. Oct 06, 2026. Epub Oct 06, 2026.
Abstract
Accurate detection of myocardial injury (MI) biomarkers for assessing anticancer drug-induced cardiotoxicity has long been constrained by insufficient capture efficiency and limited assay sensitivity. To address this challenge, we developed an electrochemiluminescence (ECL) aptasensor for the detection of cardiac troponin I (cTnI) based on a two-step sequential assembly strategy. DNA nanotetrahedron (NTH)- assembled aptamers were immobilized onto magnetic beads to form multivalent capture probes for efficient target enrichment via magnetic separation. Meanwhile, a synergistic signal probe was constructed by functionalizing terbium-based metal-organic frameworks (Tb-MOF) loaded with cadmium sulfide quantum dots (CdS QDs) with single-stranded aptamers. Specific recognition of cTnI forms a sandwich-like complex, generating a robust ECL signal for quantitative readout. A systematic comparison between one-step and two-step incubation formats revealed that the latter offers a wider linear range and a lower detection limit (0.04 pg mL-1), owing to its cleaner binding environment and reduced steric interference. Importantly, the platform was successfully applied to quantify target cTnI at cellular, animal, and clinical sample levels, demonstrating the capability for multilevel detection of drug-induced MI. These findings establish a reliable tool for evaluating drug-induced MI with high sensitivity and translational versatility, advancing precision medicine in cancer therapy.
PMID:
42839295
Bibliographic data and abstract were imported from PubMed on 07 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 12
- Comments 0